{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:24:58Z","timestamp":1792671898588,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Peritoneal mesothelioma (PM) is a\u00a0rare disease with various histopathological subtypes. For malignant peritoneal mesothelioma and borderline subgroups locoregional therapy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been implemented. The aim of our study was to retrospectively present the outcome after CRS and HIPEC for patients with different subtypes of peritoneal mesothelioma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In total 15\u00a0patients received CRS and HIPEC due to peritoneal mesothelioma at our tertiary referral hospital between 2013 and 2022. Surgical and oncologic outcomes of 14 of those patients were retrospectively evaluated as one patient was lost to follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The cohort consisted of 9\u00a0patients with diffuse malignant peritoneal mesothelioma (64.3%), 3\u00a0patients with multicystic peritoneal mesothelioma (21.4%) and 2\u00a0patients with well-differentiated peritoneal mesothelioma (14.3%). Complete cytoreduction was possible in 85.7% (<jats:italic>n<\/jats:italic>\u202f=\u200912). The major complication rate was 28.6% (<jats:italic>n<\/jats:italic>\u202f=\u20094) and the reoperation rate was 14.3% (<jats:italic>n<\/jats:italic>\u202f=\u20092). Median follow-up was 55\u00a0months (standard error, SE 15.0%, 95% confidence interval, CI 25.6\u201384.4 months). Over this time period 64.3% (<jats:italic>n<\/jats:italic>\u202f=\u20099) had no evidence of disease, 21.4% (<jats:italic>n<\/jats:italic>\u202f=\u20093) were alive with disease and 14.3% (<jats:italic>n<\/jats:italic>\u202f=\u20092) died of peritoneal mesothelioma. The median recurrence-free survival of patients was 13\u00a0months (SE\u00a013.0%, 95% CI 0.0\u201332.2 months). None of the patients with multicystic peritoneal mesothelioma had evidence of disease at the time of last follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients with peritoneal mesothelioma should receive locoregional treatment as good oncological results can be achieved with reasonable postoperative morbidity. Thus, awareness is necessary for this rare but potentially aggressive disease to offer the best medical care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-024-02460-z","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T06:02:29Z","timestamp":1729836149000},"page":"237-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma"],"prefix":"10.1007","volume":"137","author":[{"given":"Catharina","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Stift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachleitner-Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Riss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"2460_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4613-1245-1_18","volume":"81","author":"ME Kass","year":"1996","unstructured":"Kass\u00a0ME. Pathology of peritoneal mesothelioma. Cancer Treat Res. 1996;81:213\u201325.","journal-title":"Cancer Treat Res"},{"issue":"10","key":"2460_CR2","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1245\/s10434-007-9475-8","volume":"14","author":"D Baratti","year":"2007","unstructured":"Baratti\u00a0D, Kusamura\u00a0S, Nonaka\u00a0D, Oliva\u00a0GD, Laterza\u00a0B, Deraco\u00a0M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14(10):2790\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2460_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/PAS.0000000000000200","volume":"38","author":"A Churg","year":"2014","unstructured":"Churg\u00a0A, Allen\u00a0T, Borczuk\u00a0AC, Cagle\u00a0PT, Galateau-Sall\u00e9\u00a0F, Hwang\u00a0H, et\u00a0al. Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol. 2014;38(7):990\u20138.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2460_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.currproblcancer.2017.03.002","volume":"41","author":"CH Zhang","year":"2017","unstructured":"Zhang\u00a0CH, Yu\u00a0JW, Luo\u00a0M. Multicystic peritoneal mesothelioma: a\u00a0short review. Curr Probl Cancer. 2017;41(5):340\u20138.","journal-title":"Curr Probl Cancer"},{"issue":"6","key":"2460_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta\u00a0P. Epidemiology of peritoneal mesothelioma: a\u00a0review. Ann Oncol. 2007;18(6):985\u201390.","journal-title":"Ann Oncol"},{"issue":"1","key":"2460_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura\u00a0S, Kepenekian\u00a0V, Villeneuve\u00a0L, Lurvink\u00a0RJ, Govaerts\u00a0K, De Hingh\u00a0I, et\u00a0al. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36\u201359.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"2460_CR7","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1245\/s10434-023-13528-x","volume":"30","author":"L Calthorpe","year":"2023","unstructured":"Calthorpe\u00a0L, Romero-Hernandez\u00a0F, Casey\u00a0M, Nunez\u00a0M, Conroy\u00a0PC, Hirose\u00a0K, et\u00a0al. National practice patterns in malignant peritoneal mesothelioma: updates in management and survival. Ann Surg Oncol. 2023;30(8):5119\u201329.","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"2460_CR8","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan\u00a0TD, Deraco\u00a0M, Baratti\u00a0D, Kusamura\u00a0S, Elias\u00a0D, Glehen\u00a0O, et\u00a0al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J\u00a0Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol"},{"key":"2460_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet\u00a0P, Sugarbaker\u00a0PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"issue":"2","key":"2460_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo\u00a0D, Demartines\u00a0N, Clavien\u00a0PA. Classification of surgical complications: a\u00a0new proposal with evaluation in a\u00a0cohort of 6336 patients and results of a\u00a0survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"issue":"6","key":"2460_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ejso.2006.03.012","volume":"32","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker\u00a0PH, Yan\u00a0TD, Stuart\u00a0OA, Yoo\u00a0D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):686\u201391.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"2460_CR12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ejso.2008.09.010","volume":"35","author":"H Yano","year":"2009","unstructured":"Yano\u00a0H, Moran\u00a0BJ, Cecil\u00a0TD, Murphy\u00a0EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35(9):980\u20135.","journal-title":"Eur J Surg Oncol"},{"issue":"24","key":"2460_CR13","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman\u00a0AL, Libutti\u00a0SK, Pingpank\u00a0JF, Bartlett\u00a0DL, Beresnev\u00a0TH, Mavroukakis\u00a0SM, et\u00a0al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J\u00a0Clin Oncol. 2003;21(24):4560\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2460_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/jso.25642","volume":"120","author":"LS Kyang","year":"2019","unstructured":"Kyang\u00a0LS, Alzahrani\u00a0NA, Valle\u00a0SJ, Rahman\u00a0MK, Arrowaili\u00a0A, Liauw\u00a0W, et\u00a0al. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: single-institutional experience with 1225 cases. J\u00a0Surg Oncol. 2019;120(4):794\u2013802.","journal-title":"J Surg Oncol"},{"issue":"5","key":"2460_CR15","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1245\/s10434-022-13061-3","volume":"30","author":"CD Valenzuela","year":"2023","unstructured":"Valenzuela\u00a0CD, Solsky\u00a0IB, Erali\u00a0RA, Forsythe\u00a0SD, Mangieri\u00a0CW, Mainali\u00a0BB, et\u00a0al. Long-term survival in patients treated with cytoreduction and heated Intraperitoneal chemotherapy for peritoneal mesothelioma at a\u00a0single high-volume center. Ann Surg Oncol. 2023;30(5):2666\u201375.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2460_CR16","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","volume":"23","author":"S Kusamura","year":"2016","unstructured":"Kusamura\u00a0S, Torres Mesa\u00a0PA, Cabras\u00a0A, Baratti\u00a0D, Deraco\u00a0M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1468\u201373.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2460_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge\u00a0D, Zenati\u00a0MS, Austin\u00a0F, Mavanur\u00a0A, Sathaiah\u00a0M, Ramalingam\u00a0L, et\u00a0al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21(4):1159\u201365.","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"2460_CR18","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang\u00a0NJ, Rusthoven\u00a0JJ, Symanowski\u00a0J, Denham\u00a0C, Kaukel\u00a0E, Ruffie\u00a0P, et\u00a0al. Phase\u00a0III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J\u00a0Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2460_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/14737140.2017.1340157","volume":"17","author":"E Fujimoto","year":"2017","unstructured":"Fujimoto\u00a0E, Kijima\u00a0T, Kuribayashi\u00a0K, Negi\u00a0Y, Kanemura\u00a0S, Mikami\u00a0K, et\u00a0al. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17(9):865\u201372.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2460_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne\u00a0PA, Wozniak\u00a0AJ, Belani\u00a0CP, Keohan\u00a0ML, Ross\u00a0HJ, Polikoff\u00a0JA, et\u00a0al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40\u20136.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"2460_CR21","first-page":"211","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni\u00a0G, Manegold\u00a0C, Garcia\u00a0GM, Siena\u00a0S, Zielinski\u00a0CC, Amadori\u00a0D, et\u00a0al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a\u00a0platinum agent. Cancer Treat Res. 2009;64(2):211\u20138.","journal-title":"Cancer Treat Res"},{"issue":"10272","key":"2460_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas\u00a0P, Scherpereel\u00a0A, Nowak\u00a0AK, Fujimoto\u00a0N, Peters\u00a0S, Tsao\u00a0AS, et\u00a0al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (checkMate 743): a\u00a0multicentre, randomised, open-label, phase\u00a03\u00a0trial. Lancet. 2021;397(10272):375\u201386.","journal-title":"Lancet"},{"issue":"8","key":"2460_CR23","doi-asserted-by":"publisher","first-page":"e2119934","DOI":"10.1001\/jamanetworkopen.2021.19934","volume":"4","author":"K Raghav","year":"2021","unstructured":"Raghav\u00a0K, Liu\u00a0S, Overman\u00a0M, Morani\u00a0A, Willette\u00a0A, Fournier\u00a0K, et\u00a0al. Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open. 2021;4(8):e2119934.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2460_CR24","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","volume":"11","author":"K Raghav","year":"2021","unstructured":"Raghav\u00a0K, Liu\u00a0S, Overman\u00a0MJ, Willett\u00a0AF, Knafl\u00a0M, Fu\u00a0SC, et\u00a0al. Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 2021;11(11):2738\u201347.","journal-title":"Cancer Discov"},{"issue":"15","key":"2460_CR25","doi-asserted-by":"publisher","first-page":"e21094","DOI":"10.1200\/JCO.2020.38.15_suppl.e21094","volume":"38","author":"ME Marmarelis","year":"2020","unstructured":"Marmarelis\u00a0ME, Wang\u00a0X, Roshkovan\u00a0L, Walker\u00a0S, McNulty\u00a0S, Ciunci\u00a0CA, et\u00a0al. Real-world outcomes of pembrolizumab in peritoneal mesothelioma. JCO. 2020;38(15):e21094\u2013e21094.","journal-title":"JCO"},{"issue":"9","key":"2460_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.6004\/jnccn.2023.0045","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger\u00a0DS, Wood\u00a0DE, Stevenson\u00a0J, Aisner\u00a0DL, Akerley\u00a0W, Bauman\u00a0JR, et\u00a0al. Mesothelioma: peritoneal, version 2.2023, NCCN clinical practice guidelines in oncology. J\u00a0Natl Compr Canc Netw. 2023;21(9):961\u201379.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"2460_CR27","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1245\/s10434-017-6033-x","volume":"24","author":"F Le Roy","year":"2017","unstructured":"Le Roy\u00a0F, Gelli\u00a0M, Hollebecque\u00a0A, Honor\u00e9\u00a0C, Boige\u00a0V, Dartigues\u00a0P, et\u00a0al. Conversion to complete cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol. 2017;24(12):3640\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2460_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker\u00a0PH, Chang\u00a0D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2460_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12885-018-4363-0","volume":"18","author":"U Giger-Pabst","year":"2018","unstructured":"Giger-Pabst\u00a0U, Demtr\u00f6der\u00a0C, Falkenstein\u00a0TA, Ouaissi\u00a0M, G\u00f6tze\u00a0TO, Rezniczek\u00a0GA, et\u00a0al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer. 2018;18(1):442.","journal-title":"BMC Cancer"},{"issue":"3","key":"2460_CR30","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1245\/s10434-021-10983-2","volume":"29","author":"V Kepenekian","year":"2022","unstructured":"Kepenekian\u00a0V, P\u00e9ron\u00a0J, You\u00a0B, Bonnefoy\u00a0I, Villeneuve\u00a0L, Alyami\u00a0M, et\u00a0al. Non-resectable malignant peritoneal mesothelioma treated with pressurized Intraperitoneal aerosol chemotherapy (PIPAC) plus systemic chemotherapy could lead to secondary complete cytoreductive surgery: a\u00a0cohort study. Ann Surg Oncol. 2022;29(3):2104\u201313.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2460_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/bjs.7263","volume":"98","author":"TC Chua","year":"2011","unstructured":"Chua\u00a0TC, Yan\u00a0TD, Deraco\u00a0M, Glehen\u00a0O, Moran\u00a0BJ, Sugarbaker\u00a0PH. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98(1):60\u20134.","journal-title":"Br J Surg"},{"issue":"11","key":"2460_CR32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ejso.2010.08.130","volume":"36","author":"D Baratti","year":"2010","unstructured":"Baratti\u00a0D, Vaira\u00a0M, Kusamura\u00a0S, D\u2019Amico\u00a0S, Balestra\u00a0MR, Cioppa\u00a0T, et\u00a0al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a\u00a0multi-institutional series treated by cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36(11):1047\u201353.","journal-title":"Eur J Surg Oncol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02460-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02460-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02460-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:50:44Z","timestamp":1744887044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02460-z"}},"subtitle":["A\u00a0retrospective single center experience"],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":32,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2460"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02460-z","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.\u00a0M\u00fcller, M.\u00a0Bergmann, A.\u00a0Stift, T.\u00a0Bachleitner-Hofmann and S.\u00a0Riss declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (1771\/2017). All studies mentioned were in accordance with the ethical standards indicated in each case. For images or other information within the manuscript which identify patients, consent was obtained from them and\/or their legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}